TG Therapeutics, Inc. (TGTX)
USD 36.5
(1.45%)
USD 36.5
(1.45%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 198.47 Million USD | 1.6% |
| 2022 | 195.35 Million USD | -44.29% |
| 2021 | 350.66 Million USD | 28.1% |
| 2020 | 273.74 Million USD | 61.78% |
| 2019 | 169.2 Million USD | -3.06% |
| 2018 | 174.55 Million USD | 46.85% |
| 2017 | 118.86 Million USD | 50.23% |
| 2016 | 79.12 Million USD | 24.93% |
| 2015 | 63.33 Million USD | 13.35% |
| 2014 | 55.87 Million USD | 174.96% |
| 2013 | 20.32 Million USD | -21.27% |
| 2012 | 25.8 Million USD | 2826.33% |
| 2011 | 881.97 Thousand USD | -56.27% |
| 2010 | 2.01 Million USD | 13.84% |
| 2009 | 1.77 Million USD | -59.85% |
| 2008 | 4.41 Million USD | -63.66% |
| 2007 | 12.14 Million USD | 21.44% |
| 2006 | 10 Million USD | -48.34% |
| 2005 | 19.35 Million USD | 215.12% |
| 2004 | 6.14 Million USD | 29.1% |
| 2003 | 4.75 Million USD | 131.79% |
| 2002 | 2.05 Million USD | -45.06% |
| 2001 | 3.73 Million USD | -16.26% |
| 2000 | 4.46 Million USD | 43.94% |
| 1999 | 3.1 Million USD | -47.46% |
| 1998 | 5.9 Million USD | 7.27% |
| 1997 | 5.5 Million USD | 41.03% |
| 1996 | 3.9 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 56.27 Million USD | -16.29% |
| 2024 Q3 | 62.1 Million USD | 10.36% |
| 2024 Q1 | 67.22 Million USD | 38.57% |
| 2023 Q1 | 43.93 Million USD | -15.73% |
| 2023 Q3 | 47.52 Million USD | -19.23% |
| 2023 Q4 | 48.51 Million USD | 2.08% |
| 2023 FY | 198.47 Million USD | 1.6% |
| 2023 Q2 | 58.83 Million USD | 33.91% |
| 2022 FY | 195.35 Million USD | -44.29% |
| 2022 Q4 | 52.13 Million USD | 48.73% |
| 2022 Q1 | 68.65 Million USD | -27.78% |
| 2022 Q2 | 39.51 Million USD | -42.45% |
| 2022 Q3 | 35.05 Million USD | -11.28% |
| 2021 Q1 | 89.85 Million USD | 3.5% |
| 2021 Q2 | 78.88 Million USD | -12.21% |
| 2021 Q4 | 95.05 Million USD | 9.43% |
| 2021 Q3 | 86.86 Million USD | 10.11% |
| 2021 FY | 350.66 Million USD | 28.1% |
| 2020 Q3 | 85.76 Million USD | 68.54% |
| 2020 Q1 | 50.28 Million USD | 32.33% |
| 2020 Q2 | 50.88 Million USD | 1.19% |
| 2020 Q4 | 86.81 Million USD | 1.23% |
| 2020 FY | 273.74 Million USD | 61.78% |
| 2019 FY | 169.2 Million USD | -3.06% |
| 2019 Q4 | 37.99 Million USD | -37.6% |
| 2019 Q3 | 60.89 Million USD | 71.15% |
| 2019 Q2 | 35.58 Million USD | 2.46% |
| 2019 Q1 | 34.72 Million USD | -35.91% |
| 2018 FY | 174.55 Million USD | 46.85% |
| 2018 Q3 | 34.36 Million USD | -22.57% |
| 2018 Q2 | 44.38 Million USD | 6.65% |
| 2018 Q1 | 41.61 Million USD | 33.93% |
| 2018 Q4 | 54.18 Million USD | 57.68% |
| 2017 Q4 | 31.07 Million USD | -1.74% |
| 2017 FY | 118.86 Million USD | 50.23% |
| 2017 Q1 | 27.7 Million USD | 15.12% |
| 2017 Q2 | 28.46 Million USD | 2.74% |
| 2017 Q3 | 31.62 Million USD | 11.1% |
| 2016 Q1 | 14.03 Million USD | -20.63% |
| 2016 Q2 | 16.06 Million USD | 14.48% |
| 2016 FY | 79.12 Million USD | 24.93% |
| 2016 Q3 | 24.96 Million USD | 55.42% |
| 2016 Q4 | 24.06 Million USD | -3.59% |
| 2015 Q3 | 13.86 Million USD | -19.16% |
| 2015 Q1 | 14.64 Million USD | -21.95% |
| 2015 Q2 | 17.14 Million USD | 17.14% |
| 2015 Q4 | 17.67 Million USD | 27.51% |
| 2015 FY | 63.33 Million USD | 13.35% |
| 2014 Q2 | 11.99 Million USD | 56.92% |
| 2014 Q3 | 17.47 Million USD | 45.72% |
| 2014 Q4 | 18.75 Million USD | 7.33% |
| 2014 FY | 55.87 Million USD | 174.96% |
| 2014 Q1 | 7.64 Million USD | 46.53% |
| 2013 Q4 | 5.21 Million USD | 11.33% |
| 2013 Q1 | 3.75 Million USD | 44.04% |
| 2013 Q2 | 6.66 Million USD | 77.68% |
| 2013 Q3 | 4.68 Million USD | -29.72% |
| 2013 FY | 20.32 Million USD | -21.27% |
| 2012 Q1 | 17.38 Million USD | 6566.32% |
| 2012 Q4 | 2.6 Million USD | -4.03% |
| 2012 Q3 | 2.71 Million USD | -12.58% |
| 2012 Q2 | 3.1 Million USD | -82.14% |
| 2012 FY | 25.8 Million USD | 2826.33% |
| 2011 Q1 | 566.08 Thousand USD | 26.76% |
| 2011 FY | 881.97 Thousand USD | -56.27% |
| 2011 Q4 | -268.86 Thousand USD | -202.68% |
| 2011 Q2 | 322.9 Thousand USD | -42.96% |
| 2011 Q3 | 261.84 Thousand USD | -18.91% |
| 2010 Q4 | 446.56 Thousand USD | -13.39% |
| 2010 FY | 2.01 Million USD | 13.84% |
| 2010 Q2 | 525.09 Thousand USD | -0.82% |
| 2010 Q1 | 529.44 Thousand USD | 55.12% |
| 2010 Q3 | 515.63 Thousand USD | -1.8% |
| 2009 Q1 | 557.33 Thousand USD | 1166.61% |
| 2009 Q2 | 477.26 Thousand USD | -14.37% |
| 2009 Q4 | 341.32 Thousand USD | -13.73% |
| 2009 Q3 | 395.64 Thousand USD | -17.1% |
| 2009 FY | 1.77 Million USD | -59.85% |
| 2008 Q2 | 1.46 Million USD | -9.1% |
| 2008 Q3 | 1.38 Million USD | -5.71% |
| 2008 FY | 4.41 Million USD | -63.66% |
| 2008 Q4 | -52.25 Thousand USD | -103.78% |
| 2008 Q1 | 1.61 Million USD | -15.88% |
| 2007 Q4 | 1.91 Million USD | -29.12% |
| 2007 Q1 | 2.59 Million USD | -18.43% |
| 2007 Q2 | 4.92 Million USD | 89.81% |
| 2007 Q3 | 2.7 Million USD | -45.02% |
| 2007 FY | 12.14 Million USD | 21.44% |
| 2006 Q1 | 2.91 Million USD | -79.94% |
| 2006 Q4 | 3.18 Million USD | 61.81% |
| 2006 FY | 10 Million USD | -48.34% |
| 2006 Q2 | 2.35 Million USD | -19.11% |
| 2006 Q3 | 1.96 Million USD | -16.62% |
| 2005 Q1 | 1.45 Million USD | -18.67% |
| 2005 Q2 | 1.51 Million USD | 3.64% |
| 2005 Q3 | 1.86 Million USD | 23.25% |
| 2005 Q4 | 14.52 Million USD | 680.38% |
| 2005 FY | 19.35 Million USD | 215.12% |
| 2004 Q2 | 986.71 Thousand USD | -12.1% |
| 2004 Q1 | 1.12 Million USD | -26.17% |
| 2004 FY | 6.14 Million USD | 29.1% |
| 2004 Q4 | 1.79 Million USD | -20.06% |
| 2004 Q3 | 2.24 Million USD | 127.19% |
| 2003 Q4 | 1.52 Million USD | -25.43% |
| 2003 Q1 | 422.22 Thousand USD | 15.23% |
| 2003 FY | 4.75 Million USD | 131.79% |
| 2003 Q3 | 2.03 Million USD | 162.38% |
| 2003 Q2 | 777.02 Thousand USD | 84.03% |
| 2002 Q4 | 366.4 Thousand USD | -37.71% |
| 2002 FY | 2.05 Million USD | -45.06% |
| 2002 Q3 | 588.24 Thousand USD | 25.51% |
| 2002 Q2 | 468.67 Thousand USD | -25.56% |
| 2002 Q1 | 629.59 Thousand USD | 12.79% |
| 2001 Q2 | 1.17 Million USD | 33.76% |
| 2001 Q3 | 704.51 Thousand USD | -40.19% |
| 2001 Q4 | 558.19 Thousand USD | -20.77% |
| 2001 FY | 3.73 Million USD | -16.26% |
| 2001 Q1 | 880.68 Thousand USD | 149.87% |
| 2000 Q1 | 1.62 Million USD | 103.71% |
| 2000 Q4 | -1.76 Million USD | -247.57% |
| 2000 Q2 | 3.4 Million USD | 108.73% |
| 2000 Q3 | 1.19 Million USD | -64.82% |
| 2000 FY | 4.46 Million USD | 43.94% |
| 1999 Q3 | 600 Thousand USD | -14.29% |
| 1999 FY | 3.1 Million USD | -47.46% |
| 1999 Q4 | 800 Thousand USD | 33.33% |
| 1999 Q1 | 1 Million USD | -33.33% |
| 1999 Q2 | 700 Thousand USD | -30.0% |
| 1998 Q3 | 1.3 Million USD | -23.53% |
| 1998 Q1 | 1.4 Million USD | -17.65% |
| 1998 FY | 5.9 Million USD | 7.27% |
| 1998 Q4 | 1.5 Million USD | 15.38% |
| 1998 Q2 | 1.7 Million USD | 21.43% |
| 1997 Q4 | 1.7 Million USD | 54.55% |
| 1997 FY | 5.5 Million USD | 41.03% |
| 1997 Q2 | 1.8 Million USD | 100.0% |
| 1997 Q1 | 900 Thousand USD | -25.0% |
| 1997 Q3 | 1.1 Million USD | -38.89% |
| 1996 Q4 | 1.2 Million USD | 0.0% |
| 1996 FY | 3.9 Million USD | 0.0% |
| 1996 Q3 | 1.2 Million USD | 71.43% |
| 1996 Q2 | 700 Thousand USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Caribou Biosciences, Inc. | 150.53 Million USD | -31.846% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -2848.257% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -573.504% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -291.523% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -18.262% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -24.212% |
| Agenus Inc. | 78.18 Million USD | -153.86% |
| Fortress Biotech, Inc. | 200.19 Million USD | 0.859% |
| GlycoMimetics, Inc. | 39.28 Million USD | -405.215% |
| Novavax, Inc. | 779.12 Million USD | 74.526% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -17.249% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -791.902% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -105.227% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -50.161% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 1.313% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 88.974% |
| AlloVir, Inc. | 180.93 Million USD | -9.695% |
| Aptorum Group Limited | 10.56 Thousand USD | -1878330.816% |
| Ardelyx, Inc. | 169.93 Million USD | -16.793% |
| Bicycle Therapeutics plc | 216.92 Million USD | 8.504% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -15.458% |
| Chimerix, Inc. | 93.38 Million USD | -112.525% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1326.888% |
| CRISPR Therapeutics AG | 463.49 Million USD | 57.179% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -506.679% |
| Precision BioSciences, Inc. | 92.46 Million USD | -114.653% |
| Dyadic International, Inc. | 9.15 Million USD | -2068.487% |
| Elevation Oncology, Inc. | 45.44 Million USD | -336.737% |
| Fortress Biotech, Inc. | 200.19 Million USD | 0.859% |
| GT Biopharma, Inc. | 13.57 Million USD | -1361.955% |
| Alkermes plc | 996.24 Million USD | 80.078% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1129.624% |
| Innoviva, Inc. | 132.15 Million USD | -50.185% |
| IO Biotech, Inc. | 91.44 Million USD | -117.048% |
| Jaguar Health, Inc. | 42.01 Million USD | -372.391% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -135.375% |
| ContextLogic Inc. | 387 Million USD | 48.714% |
| AbCellera Biologics Inc. | 275.23 Million USD | 27.888% |
| Lantern Pharma Inc. | 17.87 Million USD | -1010.19% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2248.539% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 55.473% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 47.838% |
| MEI Pharma, Inc. | 34.78 Million USD | -470.576% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -134.283% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -716.548% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -23.63% |
| NextCure, Inc. | 67.63 Million USD | -193.441% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -506.105% |
| ChromaDex Corporation | 56.37 Million USD | -252.037% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -25.765% |
| Incyte Corporation | 1.19 Billion USD | 83.328% |
| Opthea Limited | 191.96 Million USD | -3.39% |
| MiMedx Group, Inc. | 229.72 Million USD | 13.604% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -273.59% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -112.323% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -7113.115% |
| Vaxcyte, Inc. | 468.04 Million USD | 57.595% |
| PDS Biotechnology Corporation | 43.04 Million USD | -361.085% |
| Pharming Group N.V. | 225.49 Million USD | 11.981% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -173.51% |
| Onconetix, Inc. | 34.9 Million USD | -468.575% |
| Acelyrin, Inc. | 422.06 Million USD | 52.975% |
| PureTech Health plc | 144.59 Million USD | -37.261% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -141.466% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 19.042% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -922.091% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -716.548% |
| ESSA Pharma Inc. | 32.13 Million USD | -517.646% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -52.365% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -570.388% |
| Seer, Inc. | 110.49 Million USD | -79.632% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 13.208% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -424.109% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -543.167% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1539181.837% |
| Summit Therapeutics Inc. | 87.68 Million USD | -126.347% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -435.493% |
| Senti Biosciences, Inc. | 94.7 Million USD | -109.572% |
| ImmuCell Corporation | 9.61 Million USD | -1963.716% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -545.007% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -144.843% |
| Precigen, Inc. | 84.18 Million USD | -135.772% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -249.68% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1457.155% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -60.64% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -17.834% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -4934.819% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 50.819% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -181.15% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -482.294% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -568.671% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1036.936% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -9.473% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 21.874% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -948.523% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 9.714% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 23.494% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -267.003% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -1897.204% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 23.563% |
| Aptose Biosciences Inc. | 52.35 Million USD | -279.087% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1277.306% |
| Soligenix, Inc. | 7.79 Million USD | -2446.101% |
| Century Therapeutics, Inc. | 56.07 Million USD | -253.971% |
| Kura Oncology, Inc. | 165.8 Million USD | -19.705% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -73.33% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -2285.804% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -7897.739% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -84.288% |
| Autolus Therapeutics plc | 196.72 Million USD | -0.889% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -134.446% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -70.434% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -923.964% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 38.315% |
| GRI Bio, Inc. | 11.33 Million USD | -1651.765% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -2712.974% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -51.285% |
| IGM Biosciences, Inc. | 265.59 Million USD | 25.27% |
| INmune Bio, Inc. | 29.89 Million USD | -563.885% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -15.022% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -392.319% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1142.071% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1160.835% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -219.616% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -84.59% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 28.009% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 34.16% |
| Verastem, Inc. | 92.08 Million USD | -115.537% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1006.388% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -6.865% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -63.479% |
| Histogen Inc. | 14.27 Million USD | -1290.66% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1136.748% |
| Surrozen, Inc. | 18.55 Million USD | -969.946% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1230.707% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3799.132% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -232.603% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -673.872% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -322.233% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2500.276% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -11.418% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -309.666% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 18.991% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1191.602% |
| Apollomics, Inc. | 54.14 Million USD | -266.596% |
| Amarin Corporation plc | 272.35 Million USD | 27.127% |
| Mesoblast Limited | 5.9 Million USD | -3262.843% |
| Turnstone Biologics Corp. | 78.33 Million USD | -153.357% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 18.698% |
| Synaptogenix, Inc. | 8.31 Million USD | -2287.28% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1260.723% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 21.569% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -495.483% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2147.421% |
| Exelixis, Inc. | 1.58 Billion USD | 87.492% |
| Better Therapeutics, Inc. | 38.26 Million USD | -418.726% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 14.469% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 76.792% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1580.985% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2368.009% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -561.738% |
| Gritstone bio, Inc. | 148.37 Million USD | -33.767% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -188.226% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1113.156% |
| Avid Bioservices, Inc. | 25.99 Million USD | -663.483% |
| Insmed Incorporated | 949.26 Million USD | 79.092% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1164.995% |
| MediWound Ltd. | 18.86 Million USD | -951.913% |
| OmniAb, Inc. | 83.89 Million USD | -136.575% |
| Alector, Inc. | 248.8 Million USD | 20.228% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 15.293% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -279.849% |
| Zai Lab Limited | 547.47 Million USD | 63.747% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 50.214% |
| Aura Biosciences, Inc. | 84.99 Million USD | -133.525% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 19.691% |
| Immunic, Inc. | 99.22 Million USD | -100.029% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -24.818% |
| Veracyte, Inc. | 357.93 Million USD | 44.55% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.799% |
| FibroGen, Inc. | 398.11 Million USD | 50.146% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1296.728% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -2781.483% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -2685.328% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 93.904% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -667.112% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 37.299% |
| Galecto, Inc. | 35.62 Million USD | -457.092% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -387.785% |
| Fortrea Holdings Inc. | 457.3 Million USD | 56.599% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -265.664% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -587.288% |
| XBiotech Inc. | 37.51 Million USD | -429.126% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -188.226% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -861.185% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -39.711% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -100.328% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -79.265% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 79.288% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -588.074% |
| Vaxxinity, Inc. | 56.05 Million USD | -254.097% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 53.912% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -789.691% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -79.021% |
| NexImmune, Inc. | 28.16 Million USD | -604.624% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -3488.445% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1009.263% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 92.95% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -679.587% |
| Scopus BioPharma Inc. | 11.71 Million USD | -1594.213% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -56.203% |
| Ainos, Inc. | 12.95 Million USD | -1432.31% |
| Pluri Inc. | 22.48 Million USD | -782.896% |
| Prothena Corporation plc | 282.4 Million USD | 29.72% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 0.773% |
| Celularity Inc. | 215.05 Million USD | 7.711% |
| Rallybio Corporation | 78.93 Million USD | -151.451% |
| Cue Biopharma, Inc. | 19.54 Million USD | -915.633% |
| MeiraGTx Holdings plc | 151.07 Million USD | -31.373% |
| Omeros Corporation | 94.75 Million USD | -109.47% |
| Humacyte, Inc. | 23.49 Million USD | -744.682% |
| Immunocore Holdings plc | 308.04 Million USD | 35.568% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -5754.72% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -128.487% |
| Blueprint Medicines Corporation | 722.86 Million USD | 72.543% |
| CalciMedica, Inc. | 21.81 Million USD | -809.726% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -165.838% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -15.867% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 32.707% |
| Pulmatrix, Inc. | 22.03 Million USD | -800.604% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -474.042% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -123.342% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 64.016% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -173.566% |
| Cytokinetics, Incorporated | 173.61 Million USD | -14.321% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -476.644% |
| Nutriband Inc. | 5.73 Million USD | -3361.352% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -355.082% |
| Vor Biopharma Inc. | 126.03 Million USD | -57.475% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 83.31% |
| Evogene Ltd. | 27.79 Million USD | -614.196% |
| ProKidney Corp. | 151.52 Million USD | -30.988% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -167.577% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -2480.197% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 67.687% |
| CorMedix Inc. | 48.95 Million USD | -305.4% |
| BioLineRx Ltd. | 50.8 Million USD | -290.683% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -31.702% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -421.315% |
| Atai Life Sciences N.V. | 125.78 Million USD | -57.789% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -143.112% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -143.8% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 21.412% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -506.216% |
| MediciNova, Inc. | 10.9 Million USD | -1720.827% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -54.072% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2633.995% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3195.737% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 58.335% |
| Biomea Fusion, Inc. | 126.13 Million USD | -57.351% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 84.87% |
| Mereo BioPharma Group plc | 35.84 Million USD | -453.75% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -3.865% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 13.689% |
| Absci Corporation | 73.66 Million USD | -169.426% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -619.582% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -48.57% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 18.04% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 24.26% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 4.577% |
| Allakos Inc. | 196.05 Million USD | -1.234% |
| Imunon, Inc. | 20.31 Million USD | -877.208% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -74.916% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 46.156% |
| BioAtla, Inc. | 129.68 Million USD | -53.042% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1580.985% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1152.761% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -133.725% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -375.298% |
| XOMA Corporation | 46.46 Million USD | -327.168% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -78.531% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -39.317% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1429.201% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -91.475% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -14.812% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 22.095% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -430.568% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2313.124% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1080.977% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -8628.127% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 33.691% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2849.665% |
| UroGen Pharma Ltd. | 138.88 Million USD | -42.903% |
| Sutro Biopharma, Inc. | 243 Million USD | 18.326% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -2628.32% |
| Orgenesis Inc. | 45.75 Million USD | -333.759% |
| Entera Bio Ltd. | 8.86 Million USD | -2140.124% |
| GH Research PLC | 41.22 Million USD | -381.478% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -672.036% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -138.974% |
| Xencor, Inc. | 306.97 Million USD | 35.345% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -3922.92% |
| Replimune Group, Inc. | 234.77 Million USD | 15.461% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -868.649% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -3.482% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2849.665% |
| Portage Biotech Inc. | 18.19 Million USD | -990.582% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2633.995% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -89.094% |
| OncoCyte Corporation | 25.63 Million USD | -674.174% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -3156.033% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1632.338% |
| Purple Biotech Ltd. | -22.46 Million USD | 983.407% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1104.339% |
| scPharmaceuticals Inc. | 65.17 Million USD | -204.512% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2248.056% |
| HilleVax, Inc. | 133.34 Million USD | -48.843% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -1829.752% |
| Tharimmune, Inc. | 9.45 Million USD | -1999.105% |
| Genprex, Inc. | 31.06 Million USD | -538.994% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -5.839% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -532.549% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -25844.444% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -3543.803% |
| OKYO Pharma Limited | 8243.57 USD | -2407534.071% |
| Savara Inc. | 15.74 Million USD | -1160.559% |
| Curis, Inc. | 58.35 Million USD | -240.117% |
| Daré Bioscience, Inc. | 33.6 Million USD | -490.534% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -3797.407% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2560.166% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -634.494% |
| BeiGene, Ltd. | 3.28 Billion USD | 93.961% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -895.396% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 60.207% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -29.172% |
| Erasca, Inc. | 141.52 Million USD | -40.24% |
| bluebird bio, Inc. | 240.23 Million USD | 17.382% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4284.275% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 88.634% |
| DBV Technologies S.A. | 92.16 Million USD | -115.359% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4284.275% |
| Moderna, Inc. | 6.39 Billion USD | 96.896% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -365.805% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1281.561% |
| Molecular Templates, Inc. | 63.09 Million USD | -214.585% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -197.559% |
| Travere Therapeutics, Inc. | 472 Million USD | 57.95% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -38.493% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -219.698% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -357.168% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 4.639% |
| MacroGenics, Inc. | 217.21 Million USD | 8.627% |
| RenovoRx, Inc. | 11.39 Million USD | -1641.62% |
| Adicet Bio, Inc. | 152.03 Million USD | -30.543% |
| Prime Medicine, Inc. | 186.63 Million USD | -6.342% |
| Aditxt, Inc. | 25.95 Million USD | -664.814% |
| Adagene Inc. | 41.83 Million USD | -374.465% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2615.08% |
| Quantum-Si incorporated | 111.65 Million USD | -77.751% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -15.493% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1261.491% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -454.059% |
| SciSparc Ltd. | 9.01 Million USD | -2102.586% |
| Vericel Corporation | 142.04 Million USD | -39.732% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2192.742% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -759.624% |
| Generation Bio Co. | 144.46 Million USD | -37.384% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -139.04% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -129.557% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 32.884% |
| Invivyd, Inc. | 205.75 Million USD | 3.538% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -175.052% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2016.276% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -163.74% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -1829.377% |
| 2seventy bio, Inc. | 289.88 Million USD | 31.534% |
| ADMA Biologics, Inc. | 66.58 Million USD | -198.073% |
| Clene Inc. | 41.07 Million USD | -383.225% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1449.631% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -262.207% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3195.737% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 43.623% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -440.332% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -488.458% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -91.39% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -509.025% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -16.559% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 74.147% |
| Evaxion Biotech A/S | 22.27 Million USD | -791.221% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -46.428% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 15.5% |
| Trevena, Inc. | 38.41 Million USD | -416.687% |
| Surrozen, Inc. | 18.55 Million USD | -969.946% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -148.264% |
| Cingulate Inc. | 22.75 Million USD | -772.065% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 2749.159% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -344.344% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -2310.45% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -93.525% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 73.68% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -219.739% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2170.53% |
| Kronos Bio, Inc. | 128.11 Million USD | -54.916% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -136.077% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -6666.997% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -96.847% |
| Statera Biopharma, Inc. | 28.82 Million USD | -588.444% |
| ImmunityBio, Inc. | 362.87 Million USD | 45.304% |
| Korro Bio, Inc. | 84.53 Million USD | -134.787% |
| Kineta, Inc. | 21.15 Million USD | -838.15% |
| BioVie Inc. | 31.95 Million USD | -521.201% |
| Codexis, Inc. | 66.51 Million USD | -198.378% |
| Celularity Inc. | 215.05 Million USD | 7.711% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 12.42% |
| Celcuity Inc. | 66.23 Million USD | -199.674% |
| Virax Biolabs Group Limited | 6.54 Million USD | -2931.512% |
| Cibus, Inc. | 320.3 Million USD | 38.036% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -361.57% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -486.441% |
| IN8bio, Inc. | 30.33 Million USD | -554.234% |
| Kodiak Sciences Inc. | 277.32 Million USD | 28.431% |
| Annexon, Inc. | 143.72 Million USD | -38.096% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -55.556% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -766.363% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -30911.719% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 74.541% |
| Eyenovia, Inc. | 25.4 Million USD | -681.199% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -41.45% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3468.411% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -150.812% |
| Arcellx, Inc. | 200.19 Million USD | 0.861% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -332.407% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 8.288% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -1893.321% |
| Moolec Science SA | 52.75 Million USD | -276.252% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -224.634% |
| Geron Corporation | 70.44 Million USD | -181.761% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -326.461% |
| Royalty Pharma plc | 862.4 Million USD | 76.986% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -110.982% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -2027.764% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -777.101% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 4.493% |
| Humacyte, Inc. | 23.49 Million USD | -744.682% |
| Structure Therapeutics Inc. | 102.77 Million USD | -93.116% |
| 89bio, Inc. | 151.2 Million USD | -31.263% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -147.685% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1265.028% |
| Genelux Corporation | 24.33 Million USD | -715.595% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -485.075% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -14.812% |
| Notable Labs, Ltd. | 14.77 Million USD | -1243.771% |
| Liquidia Corporation | 87.98 Million USD | -125.581% |
| Mustang Bio, Inc. | 48.5 Million USD | -309.218% |
| Immunovant, Inc. | 282.7 Million USD | 29.795% |
| Quantum-Si incorporated | 111.65 Million USD | -77.751% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -780.389% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -833.253% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -94.56% |
| Acasti Pharma Inc. | 11.3 Million USD | -1656.261% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -765.905% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1142.071% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -326.443% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -17393.257% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1149.371% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -580.711% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -379.594% |
| PepGen Inc. | 84.76 Million USD | -134.145% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -569.822% |
| United Therapeutics Corporation | 885.1 Million USD | 77.576% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -766.817% |
| Solid Biosciences Inc. | 104.31 Million USD | -90.265% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -506.484% |
| Immuneering Corporation | 58.41 Million USD | -239.779% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3799.132% |
| Silo Pharma, Inc. | 3.92 Million USD | -4960.742% |
| Belite Bio, Inc | 31.66 Million USD | -526.737% |
| XOMA Corporation | 46.46 Million USD | -327.168% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -193.819% |
| Bionomics Limited | 17.89 Billion USD | 98.891% |
| Apogee Therapeutics, Inc. | 93 Million USD | -113.407% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 656.264% |
| uniQure N.V. | 285.08 Million USD | 30.381% |
| Cassava Sciences, Inc. | 105.95 Million USD | -87.317% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2615.08% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -2.198% |
| Forte Biosciences, Inc. | 32.47 Million USD | -511.125% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -2288.745% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -575.2% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3468.411% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1296.728% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2132.816% |
| Altimmune, Inc. | 30.55 Million USD | -549.545% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 53.589% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 656.264% |
| Compugen Ltd. | 43.97 Million USD | -351.377% |
| Peak Bio, Inc. | 1249.13 USD | -15888958.785% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -167.775% |
| Benitec Biopharma Inc. | 22.38 Million USD | -786.762% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 18.387% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -595.354% |
| Zura Bio Limited | 62.63 Million USD | -216.86% |
| PolyPid Ltd. | 21.04 Million USD | -843.098% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1119.434% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -595.354% |
| Instil Bio, Inc. | 85.78 Million USD | -131.363% |
| argenx SE | 1.53 Billion USD | 87.058% |
| Immunome, Inc. | 122.82 Million USD | -61.598% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -309.455% |
| Verona Pharma plc | 67.15 Million USD | -195.564% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -666.757% |
| Shattuck Labs, Inc. | 93.61 Million USD | -112.014% |
| CervoMed Inc. | 14.95 Million USD | -1226.903% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -180.717% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2222.975% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -289.167% |
| Moolec Science SA | 52.75 Million USD | -276.252% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1106.649% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -49.73% |
| AnaptysBio, Inc. | 181.56 Million USD | -9.312% |
| Design Therapeutics, Inc. | 78.19 Million USD | -153.837% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -128.025% |
| NeurAxis, Inc. | 8.82 Million USD | -2149.978% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1477.076% |
| Lumos Pharma, Inc. | 38.66 Million USD | -413.32% |
| Achilles Therapeutics plc | 75.25 Million USD | -163.737% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -666.757% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1372.64% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -648.893% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -6666.997% |
| Nutriband Inc. | 5.73 Million USD | -3361.352% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -79.161% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -256.629% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -290.092% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -200.269% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -266.71% |
| Palisade Bio, Inc. | 13.32 Million USD | -1390.053% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -337.083% |
| Beam Therapeutics Inc. | 554.19 Million USD | 64.187% |
| Neurogene Inc. | 55.58 Million USD | -257.079% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 20.127% |
| AEON Biopharma, Inc. | 48.42 Million USD | -309.827% |
| Sesen Bio, Inc. | 78.38 Million USD | -153.218% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -137.612% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1476.838% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 55.992% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -125.822% |
| Athira Pharma, Inc. | 125.46 Million USD | -58.19% |
| Vaccinex, Inc. | 23.45 Million USD | -746.195% |
| HCW Biologics Inc. | 21.02 Million USD | -843.882% |
| XOMA Corporation | 46.46 Million USD | -327.168% |
| Nektar Therapeutics | 190.9 Million USD | -3.966% |
| Arvinas, Inc. | 480 Million USD | 58.651% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -8628.127% |
| Merus N.V. | 200.49 Million USD | 1.007% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -92.032% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -473.296% |
| Rezolute, Inc. | 70.38 Million USD | -181.977% |
| Clene Inc. | 41.07 Million USD | -383.225% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1111.804% |
| BeyondSpring Inc. | 24.86 Million USD | -698.21% |
| Synlogic, Inc. | 58.53 Million USD | -239.088% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1009.295% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -4318.411% |
| Peak Bio, Inc. | 1249.13 USD | -15888958.785% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -228.351% |
| Krystal Biotech, Inc. | 160.42 Million USD | -23.717% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 26.662% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 42.973% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -9102.572% |
| MannKind Corporation | 125.59 Million USD | -58.025% |
| Ikena Oncology, Inc. | 84.57 Million USD | -134.668% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -1957.375% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -121.51% |
| Gossamer Bio, Inc. | 183.75 Million USD | -8.008% |
| CohBar, Inc. | 12.38 Million USD | -1502.117% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -291.284% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -619.582% |
| Legend Biotech Corporation | 583.14 Million USD | 65.965% |
| Mural Oncology plc | 192.07 Million USD | -3.334% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -195.583% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1129.307% |
| Disc Medicine, Inc. | 91.12 Million USD | -117.805% |
| Champions Oncology, Inc. | 28.11 Million USD | -606.065% |
| REGENXBIO Inc. | 321.15 Million USD | 38.2% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -3602.039% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -255.971% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -409.424% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -73.557% |
| Vaxart, Inc. | 90.72 Million USD | -118.763% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2229.517% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -363.791% |
| Cellectis S.A. | 97.32 Million USD | -103.941% |
| Longeveron Inc. | 21.25 Million USD | -834.0% |
| Repare Therapeutics Inc. | 167.35 Million USD | -18.594% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 85.415% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -162.377% |
| Revolution Medicines, Inc. | 498.76 Million USD | 60.207% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -2883.689% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -351.552% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -166.088% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -185.022% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1694.53% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 95.843% |
| Denali Therapeutics Inc. | 527.23 Million USD | 62.355% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2192.742% |
| Veru Inc. | 101.34 Million USD | -95.835% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -747.93% |
| Cingulate Inc. | 22.75 Million USD | -772.065% |
| Passage Bio, Inc. | 108.38 Million USD | -83.114% |
| Context Therapeutics Inc. | 25.07 Million USD | -691.601% |
| Exicure, Inc. | 14.07 Million USD | -1310.024% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 3.683% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -358.361% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -2062.675% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 21.391% |
| Nuvalent, Inc. | 149.49 Million USD | -32.766% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2360.362% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -91.486% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -825.335% |
| OmniAb, Inc. | 83.89 Million USD | -136.575% |
| Anew Medical, Inc. | 1.3 Million USD | -15157.437% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -505.772% |
| Lipocine Inc. | 15.08 Million USD | -1216.135% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -189.69% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -160.63% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -392.319% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -72.823% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -786.682% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 70.116% |
| Ocugen, Inc. | 71.56 Million USD | -177.328% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -111.445% |
| Q32 Bio Inc. | 92.68 Million USD | -114.151% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -837.352% |
| Alumis Inc. Common Stock | 158.17 Million USD | -25.479% |
| Equillium, Inc. | 50.6 Million USD | -292.197% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -218.038% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1327.307% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -952.075% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -322.728% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -82.984% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1501.544% |
| Dominari Holdings Inc. | 23.83 Million USD | -732.704% |
| Edesa Biotech, Inc. | 9.22 Million USD | -2052.014% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1566.877% |
| Bio-Techne Corporation | 563.03 Million USD | 64.749% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 51.45% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 26.15% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -50.045% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1277.247% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -21.246% |
| Nkarta, Inc. | 131.65 Million USD | -50.76% |
| BioCardia, Inc. | 12.12 Million USD | -1537.447% |
| Iterum Therapeutics plc | 47.46 Million USD | -318.124% |